PH30348A - Azaquinoxalines and their use - Google Patents

Azaquinoxalines and their use

Info

Publication number
PH30348A
PH30348A PH46948A PH46948A PH30348A PH 30348 A PH30348 A PH 30348A PH 46948 A PH46948 A PH 46948A PH 46948 A PH46948 A PH 46948A PH 30348 A PH30348 A PH 30348A
Authority
PH
Philippines
Prior art keywords
azaquinoxalines
formula
image
substituents
compounds
Prior art date
Application number
PH46948A
Other languages
English (en)
Inventor
Uta-Maria Billhardt-Troughton
Manfred Rosner
Rudolf Bender
Christoph Meichsner
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of PH30348A publication Critical patent/PH30348A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Radar Systems Or Details Thereof (AREA)
PH46948A 1992-09-26 1993-09-24 Azaquinoxalines and their use PH30348A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4232392 1992-09-26

Publications (1)

Publication Number Publication Date
PH30348A true PH30348A (en) 1997-04-02

Family

ID=6468974

Family Applications (1)

Application Number Title Priority Date Filing Date
PH46948A PH30348A (en) 1992-09-26 1993-09-24 Azaquinoxalines and their use

Country Status (20)

Country Link
US (1) US5424311A (sr)
EP (1) EP0590428B1 (sr)
JP (1) JPH06211855A (sr)
KR (1) KR940007035A (sr)
AT (1) ATE187724T1 (sr)
AU (1) AU664643B2 (sr)
CA (1) CA2106882C (sr)
CZ (1) CZ9302005A3 (sr)
DE (1) DE59309902D1 (sr)
DK (1) DK0590428T3 (sr)
ES (1) ES2141744T3 (sr)
GR (1) GR3032520T3 (sr)
HU (1) HUT65302A (sr)
IL (1) IL107081A (sr)
MX (1) MX9305894A (sr)
NZ (1) NZ248762A (sr)
PH (1) PH30348A (sr)
PT (1) PT590428E (sr)
TW (1) TW274550B (sr)
ZA (1) ZA937081B (sr)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1599395A (en) * 1994-01-03 1995-08-01 Cocensys, Inc. 8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the use thereof as antagonists for the glycine/nmda receptor
US5801183A (en) * 1995-01-27 1998-09-01 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Aza and aza (N-oxy) analogs of glycine/NMDA receptor antagonists
US5646130A (en) * 1995-06-30 1997-07-08 Ocean University Of Oingdao Low molecular weight sulfated polysaccharides and uses thereof
ZA973884B (en) * 1996-05-23 1998-11-06 Du Pont Merck Pharma Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders
WO2000003684A2 (en) 1998-07-16 2000-01-27 Aaron Tabor Soy formulations and their use for promoting health
US6930101B1 (en) 1999-05-17 2005-08-16 The Regents Of The University Of California Thiazolopyrimidines useful as TNFα inhibitors
AU2003220401A1 (en) 2002-03-18 2003-10-08 Bristol-Myers Squibb Company Uracil derivatives as inhibitors of tnf-alpha converting enzyme (tace) and matrix metalloproteinases
US6861422B2 (en) * 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
EP1636228B1 (de) * 2003-05-23 2008-10-22 AEterna Zentaris GmbH Neue pyridopyrazine und deren verwendung als modulatoren von kinasen
DE10323345A1 (de) * 2003-05-23 2004-12-16 Zentaris Gmbh Neue Pyridopyrazine und deren Verwendung als Kinase-Inhibitoren
MY147767A (en) * 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004033670A1 (de) * 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
US7759485B2 (en) * 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US20060074088A1 (en) * 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US7728134B2 (en) * 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US20060035903A1 (en) * 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
EP1630163A1 (de) * 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP1632493A1 (de) * 2004-08-25 2006-03-08 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE102004058337A1 (de) * 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
BRPI0710658A2 (pt) * 2006-04-21 2011-08-16 Pfizer Prod Inc compostos de piridina[3,4-b] pirazinonas, seus usos na preparação de composições farmacêuticas e composições farmacêuticas compreendendo os mesmos
US7601716B2 (en) * 2006-05-01 2009-10-13 Cephalon, Inc. Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
GB0614471D0 (en) * 2006-07-20 2006-08-30 Syngenta Ltd Herbicidal Compounds
JP5513118B2 (ja) * 2006-10-19 2014-06-04 シグナル ファーマシューティカルズ，エルエルシー ヘテロアリール化合物、その組成物、及びプロテインキナーゼ阻害剤としてのそれらの使用
ZA200902384B (en) * 2006-10-19 2010-07-28 Signal Pharm Llc Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors
WO2008063455A1 (en) * 2006-11-13 2008-05-29 Hines Richard A Over-the wire exclusion device and system for delivery
CA2695406A1 (en) * 2007-08-03 2009-02-12 Boehringer Ingelheim International Gmbh Crystalline form of a dihydropteridione derivative
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
UY32306A (es) 2008-12-09 2010-07-30 Gilead Sciences Inc Derivados de pteridinona y pirimidinodiazepinona y composiciones farmacéuticas que modulan en forma selectiva los receptores tipo toll, métodos y usos
SG172958A1 (en) 2009-01-23 2011-08-29 Takeda Pharmaceutical Poly (adp-ribose) polymerase (parp) inhibitors
JP5715625B2 (ja) 2009-07-30 2015-05-07 武田薬品工業株式会社 ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤
PL2477987T3 (pl) * 2009-09-14 2018-06-29 Gilead Sciences, Inc. Modulatory receptorów toll-podobnych
WO2011053518A1 (en) 2009-10-26 2011-05-05 Signal Pharmaceuticals, Llc Methods of synthesis and purification of heteroaryl compounds
KR20120123513A (ko) * 2010-02-03 2012-11-08 시그날 파마소티칼 엘엘씨 Ｔｏｒ 키나제 억제자에 대한 민감성 예측 바이오마커로서 ｌｋｂ1 돌연변이의 동정
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
EA034512B1 (ru) 2011-10-19 2020-02-14 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Лечение злокачественной опухоли ингибиторами tor-киназы
JP2015501793A (ja) 2011-11-10 2015-01-19 オーエスアイ・ファーマシューティカルズ，エルエルシー ジヒドロプテリジノン類
BR112014013332B1 (pt) 2011-12-02 2022-09-06 Signal Pharmaceuticals, Llc Composições farmacêuticas de 7-(6-(2-hidroxi-propan-2-il)piridin-3-il)-1-((trans)-4- metoxicicloexil)-3,4-diidropirazino [2,3-b]pirazin-2(1h)-ona, uma forma sólida dessa e métodos de seu uso
AU2013202305B2 (en) 2012-02-24 2015-03-12 Signal Pharmaceuticals, Llc Methods for treating cancer using TOR kinase inhibitor combination therapy
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
AU2014207641A1 (en) 2013-01-16 2015-08-06 Signal Pharmaceuticals, Llc Substituted Pyrrolopyrimidine Compounds, compositions thereof, and methods of treatment therewith
NZ629411A (en) 2013-04-17 2017-06-30 Signal Pharm Llc Treatment of cancer with dihydropyrazino-pyrazines
ES2944478T3 (es) 2013-04-17 2023-06-21 Signal Pharm Llc 1-etil-7-(2-metil-6-(1H-1,2,4-triazol-3-il)piridin-3-il)-3,4-dihidropirazino[2,3-b]pirazin-2(1H)-ona para tratar el glioblastoma multiforme
MX2015014455A (es) 2013-04-17 2016-07-21 Signal Pharm Llc Terapia de combinacion que comprende un inhibidor de tor cinasa y n-(3-(5-fluoro-2-(4-(2-metoxietoxi)fenilamino)pirimidin-4-ilamino )fenil)acrilamida para tratar cancer.
EP2986322A1 (en) 2013-04-17 2016-02-24 Signal Pharmaceuticals, LLC Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
CN105392499B (zh) 2013-04-17 2018-07-24 西格诺药品有限公司 用于治疗癌症的包含tor激酶抑制剂和胞苷类似物的组合疗法
AU2014254058B2 (en) 2013-04-17 2019-06-06 Signal Pharmaceuticals, Llc Combination therapy comprising a Dihydropyrazino-Pyrazine Compound and an androgen receptor antagonist for treating prostate cancer
CN105324381A (zh) 2013-04-17 2016-02-10 西格诺药品有限公司 有关1-乙基-7-(2-甲基-6-(1H-1,2,4-三唑-3-基)吡啶-3-基)-3,4-二氢吡嗪并[2,3-b]吡嗪-2(1H)-酮的药物制剂、程序、固体形式和使用方法
CA3143529A1 (en) 2013-05-29 2014-12-04 Signal Pharmaceuticals, Llc Pharmaceutical compositions 0f 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
WO2015011236A1 (en) 2013-07-26 2015-01-29 Boehringer Ingelheim International Gmbh Treatment of myelodysplastic syndrome
ES2823756T3 (es) 2014-04-16 2021-05-10 Signal Pharm Llc Métodos para tratar el cáncer usando terapia de combinación de inhibidores de quinasa TOR
US9512129B2 (en) 2014-04-16 2016-12-06 Signal Pharmaceuticals, Llc Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer
US9718824B2 (en) 2014-04-16 2017-08-01 Signal Pharmaceuticals, Llc Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereof
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
TWI806081B (zh) 2014-07-11 2023-06-21 美商基利科學股份有限公司 用於治療HIV之toll樣受體調節劑
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
EA201790189A1 (ru) 2014-07-14 2017-11-30 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Способы лечения злокачественного новообразования с использованием замещенных пирролопиримидиновых соединений, композиции на их основе
PT3194401T (pt) 2014-09-16 2020-12-23 Gilead Sciences Inc Formas sólidas de modulador de recetor tipo toll
AU2015318062B2 (en) 2014-09-16 2018-07-05 Gilead Sciences, Inc. Methods of preparing toll-like receptor modulators
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
CN110996955A (zh) 2017-06-22 2020-04-10 细胞基因公司 以乙型肝炎病毒感染为特征的肝细胞癌的治疗
KR102272284B1 (ko) * 2020-01-13 2021-07-02 금오공과대학교 산학협력단 정밀 압력제어가 가능한 다단 스프링 압력제어밸브

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4077955A (en) * 1977-02-17 1978-03-07 E. R. Squibb & Sons, Inc. Amino derivatives of 1,2,3,4-tetrahydro-2-oxopyrido[2,2-b]-pyrazine carboxylic acids and esters
GR72941B (sr) * 1978-10-20 1984-01-16 Lilly Co Eli
IE58312B1 (en) * 1984-05-18 1993-09-08 Union Pharma Scient Appl Heterocyclic derivatives, processes for their preparation and drugs in which they are present, which are useful especially as aldose reductase inhibitors
JPH0276860A (ja) * 1987-10-05 1990-03-16 Toyo Jozo Co Ltd ６−置換アルコキシ−２−オキソ−１，２−ジヒドロキノキサリン誘導体
DK160876C (da) * 1987-12-08 1991-10-14 Novo Nordisk As Imidazoquinoxalinforbindelser, fremgangsmaade til deres fremstilling, anvendelse af forbindelserne og farmaceutiske praeparater, hvori forbindelserne indgaar
ATE205837T1 (de) * 1991-04-15 2001-10-15 Aventis Pharma Gmbh Chinoxaline, verfahren zu ihrer herstellung und ihre verwendung

Also Published As

Publication number Publication date
AU664643B2 (en) 1995-11-23
IL107081A0 (en) 1993-12-28
ZA937081B (en) 1994-04-18
ATE187724T1 (de) 2000-01-15
MX9305894A (es) 1994-03-31
ES2141744T3 (es) 2000-04-01
IL107081A (en) 1999-07-14
PT590428E (pt) 2000-04-28
KR940007035A (ko) 1994-04-26
DK0590428T3 (da) 2000-05-22
TW274550B (sr) 1996-04-21
DE59309902D1 (de) 2000-01-20
CA2106882A1 (en) 1994-03-27
AU4755393A (en) 1994-03-31
JPH06211855A (ja) 1994-08-02
HUT65302A (en) 1994-05-02
CZ9302005A3 (en) 1994-04-13
NZ248762A (en) 1996-01-26
EP0590428A1 (de) 1994-04-06
CA2106882C (en) 2007-04-17
HU9302696D0 (en) 1993-12-28
US5424311A (en) 1995-06-13
GR3032520T3 (en) 2000-05-31
EP0590428B1 (de) 1999-12-15

Similar Documents

Publication Publication Date Title
TW274550B (sr)
TW207533B (sr)
HU9303011D0 (en) Acyl-derivatives with antiretroviral activity
PH31682A (en) 4-Iminoquinolines, process for their preparation, and their use.
ZA938414B (en) Substituted ortho-ethenylphenylacetic acid derivatives
JPS57144278A (en) Dibenzofuran derivative, manufacture and bactericide containing same as effective component
IL65756A0 (en) N-substituted 2-methylnaphthylamides,their preparation and their use as fungicides
GR74782B (sr)
DK0584653T3 (sr)
ES8703847A1 (es) Procedimiento para la obtencion de derivados de sulfonilgua-nidinopirimidina
FI960588A0 (fi) Mikrobisideina käytettäviä tiokarbamoyyliyhdisteitä
ES8703855A1 (es) Procedimiento para la obtencion de derivados de sulfonilgua-nidinotriazina
IL95608A0 (en) 1-methoxypyrimidinyl-n-nitro-phenyl-1h,1,2,4-triazole-3-sulphonamide derivatives and herbicidal compositions containing the same
ZA874596B (en) 3-substituted 1-(2-halogenoalkoxy-benzenesulphonyl)-3-heteroaryl-(thio)ureas
ZA937179B (en) Tetrahydorindazolone pharmaceutical compositions
AU2089292A (en) Hydantoin derivatives